Provided by Tiger Fintech (Singapore) Pte. Ltd.

Xeris Pharmaceuticals Inc

5.11
-0.1600-3.04%
Post-market: 5.110.00000.00%17:52 EDT
Volume:1.52M
Turnover:7.81M
Market Cap:818.39M
PE:-16.98
High:5.28
Open:5.24
Low:5.10
Close:5.27
Loading ...

Xeris Biopharma Holdings Inc Outlook 2025 Total Revenue Guidance of $255M-$275M

THOMSON REUTERS
·
06 Mar

Xeris Biopharma Q4 Basic EPS USD -0.03

THOMSON REUTERS
·
06 Mar

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

Business Wire
·
06 Mar

Xeris Biopharma Holdings Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
04 Mar

Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?

Zacks
·
27 Feb

Press Release: Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

Dow Jones
·
27 Feb

Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks
·
26 Feb

Xeris Biopharma CEO Ken Johnson to retire, Anh Nguyen to succeed

TIPRANKS
·
24 Feb

Xeris Appoints Anh Nguyen, Md, MBA as Chief Medical Officer

THOMSON REUTERS
·
24 Feb

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Business Wire
·
24 Feb

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 50% stake, while 45% is held by institutions

Simply Wall St.
·
19 Feb

Prem Watsa's Strategic Moves: CVS Health Corp Takes Center Stage with 7.82% Portfolio Share

GuruFocus.com
·
14 Feb

Xeris to Participate in Upcoming Investor Conferences

Business Wire
·
05 Feb

the American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

THOMSON REUTERS
·
21 Jan

Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Quanterix (QTRX) and Walgreens Boots Alliance (WBA)

TIPRANKS
·
15 Jan

Xeris Biopharma Lifts 2024 Revenue Guidance

MT Newswires Live
·
10 Jan